Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: Results from a randomised double-blind placebo-controlled study

Study answer

What this study found

Vitamin D3 increased 25(OH)D levels and was associated with higher LL-37, while intestinal permeability was maintained in the active group over 3 months. In placebo, small bowel permeability increased (p=0.018) and gastro-duodenal permeability increased (p=0.030). At 3 months, participants with 25(OH)D concentrations of 75 nmol/L or higher had higher LL-37, lower CRP (p=0.019), and higher quality of life (p=0.037), but between-group differences in CDAI, CRP, fecal calprotectin, and quality of life were not significant (p=0.119, 0.624, 0.140, 0.900). No adverse events or clinical relapses…

Study & population

Randomized, double-blind, placebo-controlled trial in adults with Crohn's disease in clinical remission on stable therapy.

Intervention

Oral vitamin D3 2000 IU/day for 3 months, compared with placebo.

Key limitation

Small sample size and short 3-month duration limit confidence in clinical effects.

View full study detailsView sourceOpen PDF

Original abstract